Dr. Sallee is a child and adolescent psychiatrist and professor of psychiatry and pediatrics at the University of Cincinnati Children's Hospital Medical Center. He is former vice chairman of the department and former division chief of child psychiatry at Cincinnati Children’s Hospital Medical Center. He developed and founded the Pediatric Pharmacology Research Unit at Cincinnati Children’s Hospital and Phase 2 Discovery, Inc, a BIOSTART Company specializing in novel CNS therapeutics with annual revenues of $2.5 m. He is medical director of P2D, Inc.; director of the Division of Pharmacology Research; director of the Pediatric Pharmacology Research Unit; director of the Division of Child Psychiatry. Randy founded and directs R&D at Satiety Solutions LLC., which focuses on novel cognitive enhancing and appetite suppression molecules. He is primary investigator of project MH081854, "Cortical Excitability: Phenotype and Biomarker in ADHD Therapy. His major areas of clinical interest include Tourette disorder, pediatric psychopharmacology, ADHD, and novel GPCRs and their therapeutic potential for anxiety and obesity.